Global Injectable Suspensions Market Growth 2023-2029
LPI (LP Information)' newest research report, the “Injectable Suspensions Industry Forecast” looks at past sales and reviews total world Injectable Suspensions sales in 2022, providing a comprehensive analysis by region and market sector of projected Injectable Suspensions sales for 2023 through 2029. With Injectable Suspensions sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Injectable Suspensions industry.
This Insight Report provides a comprehensive analysis of the global Injectable Suspensions landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Injectable Suspensions portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Injectable Suspensions market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Injectable Suspensions and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Injectable Suspensions.
The global Injectable Suspensions market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Injectable Suspensions is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Injectable Suspensions is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Injectable Suspensions is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Injectable Suspensions players cover Merck Sharp & Dohme, Novo Nordisk, Lilly, Biocon, Pfizer, BeiGene, EnteraBio, AbbVie and Pfizer Limited, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Injectable Suspensions market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Intramuscular
Subcutaneous
Intravenous
Oncology
Segmentation by application
Oncology
Autoimmune disorder
Dermatologic disorders
Endocrine disorders
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck Sharp & Dohme
Novo Nordisk
Lilly
Biocon
Pfizer
BeiGene
EnteraBio
AbbVie
Pfizer Limited
Teva Pharmaceuticals
Bristol-Myers Squibb
Cipla
Baxter International
AstraZeneca
Key Questions Addressed in this Report
What is the 10-year outlook for the global Injectable Suspensions market?
What factors are driving Injectable Suspensions market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Injectable Suspensions market opportunities vary by end market size?
How does Injectable Suspensions break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Please note: The report will take approximately 2 business days to prepare and deliver.
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats
- 2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Injectable Suspensions Annual Sales 2018-2029
- 2.1.2 World Current & Future Analysis for Injectable Suspensions by Geographic Region, 2018, 2022 & 2029
- 2.1.3 World Current & Future Analysis for Injectable Suspensions by Country/Region, 2018, 2022 & 2029
- 2.2 Injectable Suspensions Segment by Type
- 2.2.1 Intramuscular
- 2.2.2 Subcutaneous
- 2.2.3 Intravenous
- 2.2.4 Oncology
- 2.3 Injectable Suspensions Sales by Type
- 2.3.1 Global Injectable Suspensions Sales Market Share by Type (2018-2023)
- 2.3.2 Global Injectable Suspensions Revenue and Market Share by Type (2018-2023)
- 2.3.3 Global Injectable Suspensions Sale Price by Type (2018-2023)
- 2.4 Injectable Suspensions Segment by Application
- 2.4.1 Oncology
- 2.4.2 Autoimmune disorder
- 2.4.3 Dermatologic disorders
- 2.4.4 Endocrine disorders
- 2.4.5 Others
- 2.5 Injectable Suspensions Sales by Application
- 2.5.1 Global Injectable Suspensions Sale Market Share by Application (2018-2023)
- 2.5.2 Global Injectable Suspensions Revenue and Market Share by Application (2018-2023)
- 2.5.3 Global Injectable Suspensions Sale Price by Application (2018-2023)
- 3 Global Injectable Suspensions by Company
- 3.1 Global Injectable Suspensions Breakdown Data by Company
- 3.1.1 Global Injectable Suspensions Annual Sales by Company (2018-2023)
- 3.1.2 Global Injectable Suspensions Sales Market Share by Company (2018-2023)
- 3.2 Global Injectable Suspensions Annual Revenue by Company (2018-2023)
- 3.2.1 Global Injectable Suspensions Revenue by Company (2018-2023)
- 3.2.2 Global Injectable Suspensions Revenue Market Share by Company (2018-2023)
- 3.3 Global Injectable Suspensions Sale Price by Company
- 3.4 Key Manufacturers Injectable Suspensions Producing Area Distribution, Sales Area, Product Type
- 3.4.1 Key Manufacturers Injectable Suspensions Product Location Distribution
- 3.4.2 Players Injectable Suspensions Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
- 4 World Historic Review for Injectable Suspensions by Geographic Region
- 4.1 World Historic Injectable Suspensions Market Size by Geographic Region (2018-2023)
- 4.1.1 Global Injectable Suspensions Annual Sales by Geographic Region (2018-2023)
- 4.1.2 Global Injectable Suspensions Annual Revenue by Geographic Region (2018-2023)
- 4.2 World Historic Injectable Suspensions Market Size by Country/Region (2018-2023)
- 4.2.1 Global Injectable Suspensions Annual Sales by Country/Region (2018-2023)
- 4.2.2 Global Injectable Suspensions Annual Revenue by Country/Region (2018-2023)
- 4.3 Americas Injectable Suspensions Sales Growth
- 4.4 APAC Injectable Suspensions Sales Growth
- 4.5 Europe Injectable Suspensions Sales Growth
- 4.6 Middle East & Africa Injectable Suspensions Sales Growth
- 5 Americas
- 5.1 Americas Injectable Suspensions Sales by Country
- 5.1.1 Americas Injectable Suspensions Sales by Country (2018-2023)
- 5.1.2 Americas Injectable Suspensions Revenue by Country (2018-2023)
- 5.2 Americas Injectable Suspensions Sales by Type
- 5.3 Americas Injectable Suspensions Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
- 6 APAC
- 6.1 APAC Injectable Suspensions Sales by Region
- 6.1.1 APAC Injectable Suspensions Sales by Region (2018-2023)
- 6.1.2 APAC Injectable Suspensions Revenue by Region (2018-2023)
- 6.2 APAC Injectable Suspensions Sales by Type
- 6.3 APAC Injectable Suspensions Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan
- 7 Europe
- 7.1 Europe Injectable Suspensions by Country
- 7.1.1 Europe Injectable Suspensions Sales by Country (2018-2023)
- 7.1.2 Europe Injectable Suspensions Revenue by Country (2018-2023)
- 7.2 Europe Injectable Suspensions Sales by Type
- 7.3 Europe Injectable Suspensions Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 8 Middle East & Africa
- 8.1 Middle East & Africa Injectable Suspensions by Country
- 8.1.1 Middle East & Africa Injectable Suspensions Sales by Country (2018-2023)
- 8.1.2 Middle East & Africa Injectable Suspensions Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Injectable Suspensions Sales by Type
- 8.3 Middle East & Africa Injectable Suspensions Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
- 9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
- 10 Manufacturing Cost Structure Analysis
- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Injectable Suspensions
- 10.3 Manufacturing Process Analysis of Injectable Suspensions
- 10.4 Industry Chain Structure of Injectable Suspensions
- 11 Marketing, Distributors and Customer
- 11.1 Sales Channel
- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Injectable Suspensions Distributors
- 11.3 Injectable Suspensions Customer
- 12 World Forecast Review for Injectable Suspensions by Geographic Region
- 12.1 Global Injectable Suspensions Market Size Forecast by Region
- 12.1.1 Global Injectable Suspensions Forecast by Region (2024-2029)
- 12.1.2 Global Injectable Suspensions Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Injectable Suspensions Forecast by Type
- 12.7 Global Injectable Suspensions Forecast by Application
- 13 Key Players Analysis
- 13.1 Merck Sharp & Dohme
- 13.1.1 Merck Sharp & Dohme Company Information
- 13.1.2 Merck Sharp & Dohme Injectable Suspensions Product Portfolios and Specifications
- 13.1.3 Merck Sharp & Dohme Injectable Suspensions Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.1.4 Merck Sharp & Dohme Main Business Overview
- 13.1.5 Merck Sharp & Dohme Latest Developments
- 13.2 Novo Nordisk
- 13.2.1 Novo Nordisk Company Information
- 13.2.2 Novo Nordisk Injectable Suspensions Product Portfolios and Specifications
- 13.2.3 Novo Nordisk Injectable Suspensions Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.2.4 Novo Nordisk Main Business Overview
- 13.2.5 Novo Nordisk Latest Developments
- 13.3 Lilly
- 13.3.1 Lilly Company Information
- 13.3.2 Lilly Injectable Suspensions Product Portfolios and Specifications
- 13.3.3 Lilly Injectable Suspensions Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.3.4 Lilly Main Business Overview
- 13.3.5 Lilly Latest Developments
- 13.4 Biocon
- 13.4.1 Biocon Company Information
- 13.4.2 Biocon Injectable Suspensions Product Portfolios and Specifications
- 13.4.3 Biocon Injectable Suspensions Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.4.4 Biocon Main Business Overview
- 13.4.5 Biocon Latest Developments
- 13.5 Pfizer
- 13.5.1 Pfizer Company Information
- 13.5.2 Pfizer Injectable Suspensions Product Portfolios and Specifications
- 13.5.3 Pfizer Injectable Suspensions Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.5.4 Pfizer Main Business Overview
- 13.5.5 Pfizer Latest Developments
- 13.6 BeiGene
- 13.6.1 BeiGene Company Information
- 13.6.2 BeiGene Injectable Suspensions Product Portfolios and Specifications
- 13.6.3 BeiGene Injectable Suspensions Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.6.4 BeiGene Main Business Overview
- 13.6.5 BeiGene Latest Developments
- 13.7 EnteraBio
- 13.7.1 EnteraBio Company Information
- 13.7.2 EnteraBio Injectable Suspensions Product Portfolios and Specifications
- 13.7.3 EnteraBio Injectable Suspensions Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.7.4 EnteraBio Main Business Overview
- 13.7.5 EnteraBio Latest Developments
- 13.8 AbbVie
- 13.8.1 AbbVie Company Information
- 13.8.2 AbbVie Injectable Suspensions Product Portfolios and Specifications
- 13.8.3 AbbVie Injectable Suspensions Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.8.4 AbbVie Main Business Overview
- 13.8.5 AbbVie Latest Developments
- 13.9 Pfizer Limited
- 13.9.1 Pfizer Limited Company Information
- 13.9.2 Pfizer Limited Injectable Suspensions Product Portfolios and Specifications
- 13.9.3 Pfizer Limited Injectable Suspensions Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.9.4 Pfizer Limited Main Business Overview
- 13.9.5 Pfizer Limited Latest Developments
- 13.10 Teva Pharmaceuticals
- 13.10.1 Teva Pharmaceuticals Company Information
- 13.10.2 Teva Pharmaceuticals Injectable Suspensions Product Portfolios and Specifications
- 13.10.3 Teva Pharmaceuticals Injectable Suspensions Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.10.4 Teva Pharmaceuticals Main Business Overview
- 13.10.5 Teva Pharmaceuticals Latest Developments
- 13.11 Bristol-Myers Squibb
- 13.11.1 Bristol-Myers Squibb Company Information
- 13.11.2 Bristol-Myers Squibb Injectable Suspensions Product Portfolios and Specifications
- 13.11.3 Bristol-Myers Squibb Injectable Suspensions Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.11.4 Bristol-Myers Squibb Main Business Overview
- 13.11.5 Bristol-Myers Squibb Latest Developments
- 13.12 Cipla
- 13.12.1 Cipla Company Information
- 13.12.2 Cipla Injectable Suspensions Product Portfolios and Specifications
- 13.12.3 Cipla Injectable Suspensions Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.12.4 Cipla Main Business Overview
- 13.12.5 Cipla Latest Developments
- 13.13 Baxter International
- 13.13.1 Baxter International Company Information
- 13.13.2 Baxter International Injectable Suspensions Product Portfolios and Specifications
- 13.13.3 Baxter International Injectable Suspensions Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.13.4 Baxter International Main Business Overview
- 13.13.5 Baxter International Latest Developments
- 13.14 AstraZeneca
- 13.14.1 AstraZeneca Company Information
- 13.14.2 AstraZeneca Injectable Suspensions Product Portfolios and Specifications
- 13.14.3 AstraZeneca Injectable Suspensions Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.14.4 AstraZeneca Main Business Overview
- 13.14.5 AstraZeneca Latest Developments
- 14 Research Findings and Conclusion
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook